activx.com
ActivX - News and Publications
http://www.activx.com/about/news.html
John W. Kozarich Receives Director of the Year Awards 2014. ASSAY and Drug Development Technologies Interview with John W. Kozarich - by Vicki Glaser. Thermo Fisher Scientific Licenses Novel Activity-Based Protein Profiling Technology from ActivX Biosciences. ActivX Biosciences Head Receives Distinguished Scientist Award. ActivX Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes. ActivX Biosciences, Inc.
activx.com
ActivX - About Us
http://www.activx.com/about/index.html
ActivX Biosciences, Inc.
activx.com
ActivX - Management
http://www.activx.com/about/management.html
John Kozarich, Ph.D, Chairman, President. Vice President, Chief Financial Officer. Lorrie Daggett, Vice President, Corporate Planning and Operations. Tyzoon Nomanbhoy, Ph.D., Director of Technology. Jonathan Rosenblum, Ph.D., Senior Director of Research. Helge Weissig, Ph.D., Director of Bioinformatics. ActivX Biosciences, Inc. A wholly owned subsidiary of Kyorin Pharmacuetical Co., Ltd.
activx.com
ActivX - Welcome
http://www.activx.com/index.html
ActivX Biosciences, Inc. A wholly owned subsidiary of Kyorin Pharmacuetical Co., Ltd.
activx.com
ActivX - Therapeutic Focus
http://www.activx.com/therapeutic-focus.html
Our current Therapeutic Focus at ActivX is in Oncology. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical state programs in both metabolic disease and oncology. ActivX's most advanced drug, KRP-104, is currently in late-stage clinical trials for the treatment of diabetes. For more information about ActivX Targeted Probes or profiling needs please contact us. ActivX Biosciences, Inc.
activx.com
ActivX - Board of Directors
http://www.activx.com/about/scientific-advisory-board.html
Paul R. Schimmel, Ph.D., Chairman, SAB. Chairman, Professor, Department of Molecular Biology and The Skaggs Institute for Chemical Biology. Benjamin Cravatt, Ph.D., (co-founder of ActivX). Professor at the Skaggs Institute for Chemical Biology at The Scripps Research Institute. Hugh Rosen, M.D., Ph.D. Professor of Immunology, and Chairman of the Committee for Advanced Human Therapeutics at The Scripps Research Institute. Dale R. Boger, Ph.D. David L. Pompliano, Ph.D. ActivX Biosciences, Inc.
activx.com
ActivX - Careers
http://www.activx.com/careers.html
ActivX Biosciences, Inc. Is an emerging biopharmaceutical company that discovers and develops small molecule drugs for major unmet medical needs. ActivX uses its unique technology to discover novel disease mechanisms and to optimize drugs that impact these diseases. There are currently no openings. For more information about ActivX Targeted Probes or profiling needs please contact us. ActivX Biosciences, Inc. Probes available from Thermo Scientific. ActivX Biosciences, Inc.
activx.com
ActivX - Board of Directors
http://www.activx.com/about/board-of-directors.html
John Kozarich, Ph.D. Mr Yoh Ito, Vice President and Chief Financial Officer of ActivX, is also the Director of Finance and Accounting of Kyorin Pharmaceutical Co. Ltd. He joined Kyorin in 2003 and previously held the position of Senior Manager of Strategies and Business Development Headquarters. Prior to Kyorin, Mr. Ito was Managing Director of Capital Arts, Inc. He received his MBA from Cornell University and graduated from the University of Tokyo. Masakatsu Komuro, Ph.D. Koichiro Hagihara, Ph.D.